Hemispherian's GLIX1 to treat malignant glioma receives US FDA orphan drug designation
Hemispherian AS, an Oslo-based pharmaceutical company focused on developing breakthrough cancer therapies, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for GLIX1 for the treatment of malignant glioma, a …